Every 8-K that Travere Therapeutics, Inc. (TVTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TVTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TVTX filings page.
Travere Therapeutics, Inc. (TVTX) announced a planned leadership transition in which Eric Dube, Ph.D., will step down as President, Chief Executive Officer and Board member effective December 1, 2026, then serve as Executive Advisor through February 15, 2027 and as a consultant for up to 18 months. Bradley L. Campbell, formerly President and CEO of Amicus Therapeutics, will become President, CEO and a Board member as of the same date under an employment agreement that includes a $1,000,000 annual base salary, a target bonus of 85% of base salary, and initial equity awards valued at about $16.5 million in stock options and time-based RSUs, plus a further $3.75 million performance-based RSU grant expected in early 2027. Both Dr. Dube’s transition package and Mr. Campbell’s agreement include detailed vesting, consulting and severance protections, with enhanced equity acceleration and cash severance if a qualifying termination occurs around a Change in Control.
Travere Therapeutics reported second quarter 2026 results driven by FILSPARI demand in IgA nephropathy and FSGS. U.S. net product sales rose to $161.4 million from $94.8 million, including FILSPARI sales of $141.1 million, and 2,012 new patient start forms. A recognized inducement expense of $40.0 million related to 2029 convertible note repurchases contributed to a GAAP net loss of $34.8 million or $0.37 per share; non-GAAP net loss was $9.0 million or $0.10 per share. Cash, cash equivalents, and marketable securities totaled $489.2 million as of June 30, 2026, after issuing $525 million of 0.5% convertible notes due 2032 and repurchasing approximately $221 million of 2.25% notes due 2029.
Travere advanced its rare kidney disease portfolio. FILSPARI received U.S. approval in April 2026 to reduce proteinuria in FSGS patients without nephrotic syndrome, with a U.S. addressable population above 30,000 and a U.S. patent allowance expected to extend IgA nephropathy method-of-use coverage into October 2037. The pivotal Phase 3 HARMONY Study of pegtibatinase in classical homocystinuria continues enrolling, with topline data expected in 2H 2027. The company also closed an exclusive licensing and collaboration agreement for civorebrutinib, paying $112.5 million upfront for rights outside Greater China and certain Asian countries, and plans to study it across multiple immune-mediated kidney diseases.
Travere Therapeutics, Inc. reported that its chief accounting officer and principal accounting officer, Sandra Calvin, plans to retire after the filing of the company’s Annual Report on Form 10-K expected in February 2027. The company expects Vice President, Controller John Torell, a CFA and CPA, to assume the CAO and PAO roles, with the board planning to appoint him before her retirement to allow for an orderly transition of responsibilities.
Travere Therapeutics announced that Chief Research Officer William Rote, Ph.D. plans to retire from the company effective February 17, 2027, which marks the 10-year anniversary of his employment. He is expected to remain in his current role until that date and support a smooth transition.
The responsibilities currently overseen by Dr. Rote are expected to be assumed by Jula Inrig, M.D., the company’s Chief Medical Officer. Effective July 1, 2026, Dr. Inrig will be named Executive Vice President, Head of Research & Development and Chief Medical Officer. Travere also expects to enter into a consulting arrangement with Dr. Rote following his retirement to maintain access to his expertise.
Travere Therapeutics entered a major license and collaboration agreement with Everest Medicines for civorebrutinib (EVER001), a covalent reversible Bruton’s tyrosine kinase inhibitor. Travere receives exclusive rights to develop and commercialize the drug for prophylactic, diagnostic and therapeutic uses in a broad field across territories outside China and certain East and Southeast Asian countries.
Travere will pay Everest an upfront $112.5 million, with Everest eligible for up to approximately $1.03 billion in additional clinical, regulatory and commercial milestone payments across up to five indications, plus tiered royalties from high single-digit to double-digit percentages on net sales. Travere leads development and commercialization in its territory, shares costs for global trials, and both parties agree to a 10‑year non-compete on competing BTK products. The agreement becomes effective after customary conditions, including expiration or termination of the Hart‑Scott‑Rodino waiting period.
Travere Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where stockholders approved an amendment to the 2018 Equity Incentive Plan to authorize an additional 3,000,000 shares of common stock for equity awards. All ten director nominees were elected, executive compensation received advisory approval, and stockholders indicated a preference for annual advisory votes on pay. Stockholders also ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026.
Travere Therapeutics completed a registered underwritten public offering of $525.0 million aggregate principal amount of 0.50% Convertible Senior Notes due 2032. The notes are senior unsecured, pay 0.50% interest semi-annually, and mature on May 15, 2032, unless earlier repurchased, redeemed or converted.
The initial conversion rate is 15.4078 shares per $1,000 principal (conversion price about $64.90 per share), with a maximum of 11,729,182 shares issuable based on an initial maximum conversion rate of 22.3413. Travere estimates net proceeds of about $508.5 million.
The company intends to use roughly $350.9 million of the proceeds to repurchase about $221.4 million principal of its outstanding 2.25% senior convertible notes due 2029 and will use the remaining proceeds for general corporate purposes, including commercialization, R&D, capital expenditures, working capital and administrative expenses.
Travere Therapeutics reported strong first quarter 2026 growth driven by FILSPARI. Total revenue was $127.2 million, up from $81.7 million a year earlier, as U.S. net product sales rose to $124.5 million, largely from FILSPARI. GAAP net loss narrowed to $37.1 million, or $0.40 per share, while non-GAAP results improved to net income of $4.1 million, or $0.05 per share. FILSPARI U.S. net product sales reached $105.2 million, an 88% year-over-year increase, supported by 993 new patient start forms for IgA nephropathy. The FDA also approved FILSPARI for focal segmental glomerulosclerosis, expanding the U.S. addressable population for FILSPARI to more than 100,000 patients. Travere restarted enrollment in its Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria and ended the quarter with $264.7 million in cash, cash equivalents and marketable securities.
Travere Therapeutics reported that the FDA approved FILSPARI (sparsentan) to reduce proteinuria in adults and children 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. FILSPARI is now the first and only FDA‑approved medicine specifically for FSGS, expanding its use beyond IgA nephropathy into a second rare kidney disease.
The company estimates a U.S. addressable population of more than 30,000 FSGS patients without nephrotic syndrome. In the Phase 3 DUPLEX study, FILSPARI cut proteinuria by 46% from baseline to Week 108 in the overall population versus 30% with irbesartan, and by 48% versus 27% in patients without nephrotic syndrome, with statistically significant results. FILSPARI also showed a modest eGFR benefit and was generally well tolerated with a safety profile comparable to irbesartan.
Travere Therapeutics reported strong growth for 2025 driven by its kidney drug FILSPARI. Fourth-quarter U.S. net product sales were $126.6 million, up from $73.5 million a year earlier, with FILSPARI contributing $103.3 million, a 108% increase. Full-year U.S. net product sales reached $410.5 million, compared with $226.7 million in 2024, including FILSPARI net product sales of $322.0 million, up 144%.
GAAP net income for Q4 2025 was $2.7 million, versus a loss of $60.3 million in Q4 2024, while full-year GAAP net loss narrowed to $25.5 million from $321.5 million. On a non-GAAP basis, the company reported Q4 net income of $33.3 million and full-year 2025 net income of $81.1 million.
Cash, cash equivalents and marketable securities totaled $322.8 million as of December 31, 2025, and Travere expects a $25 million sales-based milestone from Mirum in the first half of 2026. The FDA is reviewing a supplemental application for FILSPARI in FSGS with a PDUFA target action date of April 13, 2026. Enrollment has resumed in the Phase 3 HARMONY trial of pegtibatinase for classical homocystinuria.
Travere Therapeutics reported that the U.S. FDA has extended the review timeline for its supplemental New Drug Application for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS). The new PDUFA target action date is April 13, 2026, following the company’s recent submission of additional information requested by the FDA to further characterize FILSPARI’s clinical benefit.
The FDA classified the submission as a Major Amendment to the application and extended the review period accordingly, and has not requested any new safety or manufacturing data. If ultimately approved, FILSPARI would be the first medication indicated for FSGS, a rare kidney disease with no FDA-approved pharmacologic therapies, and would add to FILSPARI’s existing full approvals in the U.S. and EU for slowing kidney function decline in adults with IgA nephropathy.
Travere Therapeutics, Inc. filed a current report stating that on January 12, 2026 it issued a press release with certain preliminary financial results for the fourth quarter and full year ended December 31, 2025. The company is furnishing this information under a section that keeps the press release and related details from being treated as formally filed or automatically incorporated into other regulatory documents. The press release is included as Exhibit 99.1, and the report also includes a cover page interactive data file as Exhibit 104.
Travere Therapeutics (TVTX) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The materials are included as Exhibit 99.1 and are furnished under Item 2.02, meaning they are not deemed filed for Section 18 liability. The company also included Exhibit 104, the cover page iXBRL data file.
Travere’s common stock trades on the Nasdaq Global Market under the symbol TVTX.
Travere Therapeutics reports that the U.S. FDA has informed the company an advisory committee is no longer needed for its supplemental new drug application (sNDA) for FILSPARI in focal segmental glomerulosclerosis (FSGS). The sNDA remains under review with a Prescription Drug User Fee Act (PDUFA) target action date of January 13, 2026.
If approved, FILSPARI would be the first medication indicated for FSGS, a rare kidney disorder that causes protein in the urine and progressive kidney damage. The filing highlights Phase 3 DUPLEX and Phase 2 DUET studies, where FILSPARI showed rapid, superior and sustained reductions in proteinuria versus maximally dosed irbesartan in adult and pediatric patients, and a safety profile comparable to irbesartan.
The DUPLEX study showed statistically significant and clinically meaningful proteinuria remission at 36 weeks that was durable through 2 years, and patients achieving partial or complete remission had a 67% to 77% lower risk of kidney failure. FILSPARI is already fully approved in the U.S. and EU to slow kidney function decline in adults with IgA nephropathy.